Abstract:Introduction: Endothelial dysfunction is considered a key contributor to vascular pathologies. It is well-accepted that excessive reactive oxygen species and oxidative damage likely contribute to endothelial dysfunction. The transcription factor nuclear factor erythroid 2-related factor 2 (Nrf2) is considered the master regulator of endogenous antioxidant responses. Therefore, Nrf2 may be a potential therapeutic target to protect against endothelial dysfunction. However, the roles of endothelial cell (EC)-specific Nrf2 on endothelial function are not known. The major objective of this study was to evaluate the impacts of EC Nrf2 deletion on endothelial-mediated vasodilation, which we hypothesized would be attenuated with EC Nrf2 deletion. Methods: Femoral-to-popliteal artery segments were harvested from 6-mo old C57BL/6 mice (WT, n = 6) and EC-specific Nrf2-knockout mice (Tie2-Cre-Nrf2 floxed-KO, n = 6) using both sexes (3 male and 3 female/group). Vasodilation was assessed in response to flow (30 uL·min -1 ), acetylcholine (ACh, 10 -7 -10 -3 M) with and without NΩ-Nitro-L-arginine methyl ester (L-NAME), and sodium nitroprusside (SNP, 10 -9 -10 -4 M) using videomicroscopy. Glutathione peroxidase 1 (GPX1) and catalase (CAT) skeletal muscle protein expression was assessed by immunoblotting and normalized to total protein. Results: Endothelium-dependent vasodilation was lower in Nrf2-KO compared to WT induced by flow (WT: 34.8 ± 2.9%, Nrf2-KO: 20.7 ± 3.7%, P < 0.01) and ACh (10 -3 M, WT: 68.3 ± 8.2%, Nrf2-KO: 44.5 ± 7.1%, P < 0.01). L-NAME incubation attenuated endothelium-dependent vasodilation in WT mice in response to flow (12.8 ± 4.5%, P < 0.01) and ACh (10 -3 M, 19.1 ± 4.4%, P < 0.01) but did not change in Nrf2-KO in response to flow (15.6 ± 6.8%, P = 0.28) or ACh (10 -3 M, 37.7 ± 7.0%, P = 0.16). Endothelium-independent vasodilation was not different (SNP 10 -4 M, WT: 92.7 ± 3.6%, Nrf2-KO: 81.9 ± 10.2%, P = 0.16). In addition, GPX1 was lower in Nrf2-KO mice (WT: 0.47 ± 0.06, Nrf2-KO: 0.001 ± 0.003, P < 0.01), but CAT was not different (WT: 0.16 ± 0.04, Nrf2-KO: 0.37 ± 0.21, P = 0.08). Conclusions: EC Nrf2 may play a key role in endothelial-mediated vasodilatory function. The nitric oxide synthase inhibitor L-NAME attenuated endothelial-mediated vasodilation in WT but not in EC Nrf2-KO. EC Nrf2 may play a role in skeletal muscle antioxidant homeostasis, which suggests potential systemic implications of EC Nrf2 deletion. These results suggest that the EC antioxidant defense system is linked to endothelial dysfunction and changes in the skeletal muscle redox environment, likely through nitric oxide- and oxidative stress-related mechanisms. NIH (R01 AG034995, R01 AG049868, P01HL62222) NIH National Institute of General Medical Sciences, which funds the Great Plains IDeA-CTR Network (U54GM115458) This is the full abstract presented at the American Physiology Summit 2023 meeting and is only available in HTML format. There are no additional versions or additional content available for this abstract. Physiology was not involved in the peer review process.

Abstract 4141823: Deletion of Endothelial Neuropilin-1 Improves Cardiac Diastolic Function in Heart Failure with Preserved Ejection Fraction

Endothelial S1pr1 Regulates Pressure Overload‐induced Cardiac Remodelling Through AKT‐eNOS Pathway

Retracted: the Correlation Between Angiogenesis and Abnormal Expression of SERCA2a, Phospholamban and the Endothelin Pathway in Heart Failure, and Improvement by Puerarin

Cardiomyopathy and Worsened Ischemic Heart Failure in SM22-α Cre-Mediated Neuropilin-1 Null Mice

Endothelial Forkhead Box Transcription Factor P1 Regulates Pathological Cardiac Remodeling Through Transforming Growth Factor-β1–Endothelin-1 Signal Pathway

Neuropilin‐1 Maintains Dimethylarginine Dimethylaminohydrolase 1 Expression in Endothelial Cells, and Contributes to Protection from Angiotensin II–induced Hypertension

Abstract 4142757: Adiponectin Receptor Agonist Alleviates Heart Failure with Preserved Ejection Fraction by Regulating NLRP3/Caspase-1/IL-1β and Pl3K/Akt Signaling Pathway

Abstract 12878: Inhibition of NK1.1 Signaling Attenuates Pressure Overload-Induced Cardiopulmonary Inflammation, Pulmonary IFN-γ Production, and Heart Failure Progression

Cell therapy attenuates endothelial dysfunction in hypertensive rats with heart failure and preserved ejection fraction

Neuregulin-1β Partially Improves Cardiac Function in Volume-Overload Heart Failure Through Regulation of Abnormal Calcium Handling.

Cardiomyopathy and Worsened Ischemic Heart Failure in SM22-α Cre-Mediated Neuropilin-1 Null Mice: Dysregulation of PGC1α and Mitochondrial Homeostasis.

HMGB1‐Promoted Neutrophil Extracellular Traps Contribute to Cardiac Diastolic Dysfunction in Mice

Abstract 15000: Renal Denervation Improves Cardiac Function and Mitigates Pathophysiological Changes in a Novel Murine Model of Heart Failure With Preserved Ejection Fraction

Interleukin-1β Disruption Protects Male Mice From Heart Failure With Preserved Ejection Fraction Pathogenesis

Cardiomyopathy and Worsened Ischemic Heart Failure in SM22-&agr; Cre-Mediated Neuropilin-1 Null Mice: Dysregulation of PGC1&agr; and Mitochondrial Homeostasis

The NLRP3-inflammasome inhibitor MCC950 improves cardiac function in a HFpEF mouse model

Endothelial Nrf2-KO Attenuates Endothelial Function and Skeletal Muscle Antioxidant Capacity

Abstract P3023: The Regulatory Role Of Mir-21 In Heart Failure With Preserved Ejection Fraction (hfpef)

Abstract P3094: Mir-181c-5p As Detrimental Player In A Mouse Model Of Cardiorenal Syndrome With Thrombotic Microangiopathy

Endothelial-Mesenchymal Transition in Heart Failure With a Preserved Ejection Fraction: Insights Into the Cardiorenal Syndrome

Differentially Expressed Lnc-Nos2p3-mir-939-5p Axis in Chronic Heart Failure Inhibits Myocardial and Endothelial Cells Apoptosis Via Inos/tnfα Pathway.